Growing evidence supports the utility of biomarkers such as Galectin-3 (Gal-3), soluble ST2 (sST2), and soluble urokinase plasminogen activator receptor (suPAR) for risk stratification in heart failure, including HIV-associated cardiomyopathy. The gene discussed is LGALS3; the disease is heart failure.